Gottfried E. Konecny, MD, on Targeting Folate Receptor Alpha in Ovarian Cancer

Posted: Friday, February 28, 2025

Gottfried E. Konecny, MD, of David Geffen School of Medicine, University of California, Los Angeles, discusses the role of folate receptor alpha (FRa) in targeted therapy for ovarian cancer. After sharing trial results with the FRa antibody-drug conjugate mirvetuximab soravtansine-gynx as well as its toxicity profile, he mentions a few other agents in the pipeline that target FRa in the treatment of ovarian cancer.

---